Literature DB >> 22104434

Pathological outcomes of men eligible for active surveillance after undergoing radical prostatectomy: are results predictable?

Turang Ed Behbahani1, Jörg Ellinger, Daniel Garcia Caratozzolo, Stefan C Müller.   

Abstract

INTRODUCTION: To analyze pathological results in patients with prostate cancer eligible for active surveillance (AS) after radical prostatectomy and available prediction systems.
METHODS: A retrospective analysis was performed of 612 patients who underwent radical prostatectomy during a 14-year period. Subsequently, we selected those patients who would have been eligible for AS according to 2 different published criteria. Group AS-A matched the following criteria: ≤T2a; Gleason Score ≤6; and prostate-specific antigen <10 ng/mL, while group AS-B applied to different criteria: ≤T2a; Gleason Score <7; and prostate-specific antigen ≤15 ng/mL. Pathological outcomes were compared with results of the 2001 Partin tables.
RESULTS: Altogether, 125 (20.4%) patients were included in group AS-A and 159 (25.9%) in group AS-B. We detected 32 cases of >pT2c (25.6%) for group AS-A and 47 cases (29.6%) for AS-B, respectively. Gleason score upgrading was recorded in 34.4% (AS-A) and 38.3% (AS-B). Results of the Partin tables showed good discrimination among patients at risk for positive lymph nodes but limited discrimination for organ-confined disease, seminal vesicle.
CONCLUSIONS: Overall >25% of patients eligible for AS showed either upstaging or Gleason score upgrading, which could not be measured with the examined predictive tools. Patients should be informed about the risks of inaccurate preoperative diagnostic.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104434     DOI: 10.1016/j.clgc.2011.09.004

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  3 in total

1.  Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.

Authors:  Mehmet Ilker Gokce; Semih Tangal; Nurullah Hamidi; Evren Suer; Muhammed Arif Ibis; Yasar Beduk
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

2.  Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

Authors:  Baris Turkbey; Haresh Mani; Omer Aras; Jennifer Ho; Anthony Hoang; Ardeshir R Rastinehad; Harsh Agarwal; Vijay Shah; Marcelino Bernardo; Yuxi Pang; Dagane Daar; Yolanda L McKinney; W Marston Linehan; Aradhana Kaushal; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2013-03-06       Impact factor: 11.105

3.  The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Authors:  Hiromi Hirama; Mikio Sugimoto; Kazuto Ito; Taizo Shiraishi; Yoshiyuki Kakehi
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-19       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.